MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
121 hedge funds and large institutions have $1.26B invested in MyoKardia, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 31 reducing their positions, and 23 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 31
30% more capital invested
Capital invested by funds: $974M → $1.26B (+$289M)
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
5% more funds holding
Funds holding: 115 → 121 (+6)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $863K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.4M |
| 2 |
BlackRock
New York
|
+$20.1M |
| 3 |
Millennium Management
New York
|
+$18.9M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$18M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$14M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12.5M |
| 3 |
VMI
VHCP Management II
New York
|
-$11.4M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.5M |
| 5 |
D.E. Shaw & Co
New York
|
-$6.11M |
MYOK Hedge Fund Activity: Q4 2017 in Review
121 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q4 2017, worth a combined $1.26B — up 30% from $974M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new MYOK positions and 23 closed out — a net gain of 6 holders — while 50 added to existing stakes and 31 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $21.4M. The largest seller was Deerfield Management, cutting an estimated $14M.
- 121 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q4 2017, up from 115 in Q3 2017.
- Funds reported $1.26B of MyoKardia, Inc. Common Stock stock for Q4 2017, up 30% quarter-over-quarter.
- 29 funds opened new MyoKardia, Inc. Common Stock positions in Q4 2017 and 23 closed out, a net change of +6 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q4 2017 was T. Rowe Price Associates, an estimated $21.4M added.
- The largest MyoKardia, Inc. Common Stock seller in Q4 2017 was Deerfield Management, an estimated $14M sold.
Based on aggregated 13F filings for Q4 2017.